-+ 0.00%
-+ 0.00%
-+ 0.00%

*Kalaris Currently Enrolling Phase 1, Single Ascending Dose Trial of TH103 in Neovascular Age-related Macular Degeneration Patients >KLRS

Dow Jones·08/13/2025 12:03:00

Please log in to view news